Hims & Hers falls after 'conservative' forecasts

Shares of telehealth firm Hims & Hers Health HIMS.N fall 6.61% to $39.11 premarket

Co sees Q2 revenue to be between $530 million and $550 million, below estimates of $564.6 million - data compiled by LSEG

HIMS expects onetime quarter-over-quarter revenue drop in Q2, as it transitions subscribers previously on commercially available dosages of Novo Nordisk's NOVOb.CO semaglutide to options on its or other platforms by end of quarter

Reaffirms full-year revenue forecast of $2.3 billion to $2.4 billion

We suspect that the re-affirmed 2025 and new Q2 forecast is likely "conservative," brokerage BTIG says

Q1 revenue of $586.0 million beats estimates of $538.2 million

Up to last close, stock up ~73% YTD